Moderna, Q4

Moderna's Q4 Loss Wider Than Expected
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 vaccine sales.
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
Key Takeaways Moderna reported a larger loss than analysts had expected for the fourth quarter on Friday.The COVID vaccine maker said it expects 2025 sales between $1.5 billion and $2.5 billion, well below the analyst consensus.
Moderna swings to Q4 loss after nearly 66% drop in revenue
Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here.
Moderna Reports Higher-Than-Expected Losses While Anticipating Layoffs
In its fourth-quarter earnings report, Moderna’s revenue was down substantially from 2023. Separately, media reports reveal anticipated cuts to the company’s digital team.
Moderna posts bigger loss than expected as it scales down manufacturing
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine. The company reported a quarterly loss of $2.
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.
Moderna Inc (MRNA) Q4 2024 Earnings Call Highlights: Navigating Challenges and Strategic Shifts
Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...
FiercePharma1d
Moderna shoulders $238M contract manufacturing cancellation charge in Q4
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Moderna reports Q4 EPS ($2.91), consensus ($2.76)
Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...
2MRNA : Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Yahoo Finance7d
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?
We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Moderna: Q4 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter. On a per-share basis, the Cambridge, Massachusetts-based company ...
Stocktwits on MSN22h
Moderna’s Q4 Losses Worse Than Feared, But Revenue Beat And Cost Cuts Boost Stock — Retail Sentiment Follows
Moderna, Inc. (MRNA) shares were up over 3% in choppy trading on Friday afternoon, even as the biotech firm reported a ...